The use and importance of liposomes in Positron Emission Tomography

Drug Delivery

Volumn 19, Issue 1, 2012, Pages 68-80

  Silindir, Mine ^a   Özer, A Yekta ^a   Erdogǎan, Suna ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

applications of PET radiopharmaceuticals; drug delivery systems; liposomes for PET; Positron Emission Tomography (PET); Target imaging with liposomes

Indexed keywords

ALBUMIN MICROSPHERE; AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTAGEN; ARIKACE; CARBON NANOTUBE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENBUCRILATE; ERYTHROMYCIN; FLUORODEOXYGLUCOSE F 18; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEXAPEL; INFLUENZA VACCINE; LANTHANIDE; LEP ETU; LIPOPLATIN; LIPOSOME; MORPHINE SULFATE; MURAMYL TRIPEPTIDE; NYSTATIN; PACLITAXEL; PROSTAGLANDIN E1; QUANTUM DOT; RADIOISOTOPE; RETINOIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THERMODOX; UNCLASSIFIED DRUG; VERTEPORFIN; VESCAN; VINCRISTINE; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; BACTERIAL INFECTION; BREAST CANCER; BREATHING DISORDER; CARDIOLOGY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; ENTERITIS; HEAD AND NECK CANCER; HEART INFARCTION; HEPATITIS A; HEPATITIS B; HUMAN; INFLUENZA; ISOTOPE LABELING; KAPOSI SARCOMA; LUNG CANCER; LUNG INFECTION; MENINGITIS; MYCOSIS; MYOPIA; NEOPLASM; NEUROLOGY; NONHUMAN; OCULAR HISTOPLASMOSIS; ONCOLOGY; OSTEOARTHRITIS; OVARY CANCER; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PSYCHIATRY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; UVEA MELANOMA; VASCULITIS;

ANIMALS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES;

EID: 84855372887     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.635721     Document Type: Review

References (150)

1. Ahluwalia BD. (2000). Tomographic methods in nuclear medicinephysical principles, instruments and clinical applications. Florida, USA: CRC Press Inc Boca Raton.
2. Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, Bockisch A. (2002). Whole-body Positron Emission Tomography-CT: optimized CT using oral and i.v. contrast materials. Am J Roentgenol, 176, 1555-60. (Pubitemid 35386660)
3. Apolo AB, Pandit-Taskar N, Morris MJ. (2008). Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med, 49, 2031-41.
4. Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, Ozguven MA. (2011). Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fuoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med, 25, 406-13.
5. Avila-Rodriguez MA, Selwyn RG, Hampel JA, Tomadsen BR, Dejesus OT, Converse AK, Nickles RJ. (2007). Positron-emitting resin microspheres as surrogates of 90Y SIR-Spheres: a radiolabeling and stability study. Nucl Med Biol, 34, 585-90. (Pubitemid 46963020)
6. Bae KH, Chung HJ, Park TG. (2011). Nanomaterials for cancer therapy and imaging. Mol Cells [Epub ahead of print].
7. Bailey DL, Townsend DW, Valk PE, Maisey MN. (2005). Positron emission tomography. London, UK: Basic Sciences, Springer-Verlag.
8. Baker RA. (2009). Parkinson's disease and growth factors-are they the answer? Parkinsonism and Relat Disord, 15S3, S181-S4.
9. Bangham AD, Standish MM, Watkins JC. (1965). Difusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 13, 238-52.
10. Basu S, Zhuang H, Torigian D, Rosenbaum J, Chen W, Alavi A. (2009). Functional imaging of infammatory diseases using nuclear medicine techniques. Semin Nucl Med, 39, 124-45.
11. Beller GA. (2010). Recent advances and future trends in multimodality cardiac imaging. Heart Lung Circ, 19, 193-209.
12. Betageri GV. (1993). Liposome drug delivery systems. USA: Technomics Publishing.
13. Blakey DC. (1992). Drug targeting with monoclonal antibodies. A review. Acta Oncol, 31, 91-7.
14. Boddapati SV, D'Souza GG, Weissig V. (2010). Liposomes for drug delivery to mitochondria. Methods Mol Biol, 605, 295-303.
15. Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP, Weissig V. (2005). Mitochondriotropic liposomes. J Liposome Res, 15, 49-58. (Pubitemid 40976306)
16. Boellaard R. (2007). Obtaining cardiac images from positron emission tomography, computed tomography, and magnetic resonance imaging: physical principles. Heart Metab, 34, 33-7. (Pubitemid 46597135)
17. Bonaventure T, Goéré D, Boige V, Pocard M. (2009). Beware of PET-CT results in cases of cancer occurring in the setting of chronic infammatory bowel disease. J Chir (Paris), 146, 579-82.
18. Cai W, Chen X. (2008). Multimodality molecular imaging of tumor angiogenesis. J Nucl Med, 49, 113S-28S. (Pubitemid 351948040)
19. Cetina L, Serrano A, Cantú-de-León D, Pérez-Montiel D, Estrada E, Coronel J, Hernández-Lucio M, Duenas-González A. F18-FDGPET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Rev Invest Clin, 63, 227-35.
20. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL. (2002). The development of [124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res, 62, 5912-9. (Pubitemid 35204754)
21. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Zubal G, Cronin V. (2006). Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med, 47, 885-95. (Pubitemid 46768453)
22. Ducongé F, Pons T, Pestourie C, Hérin L, Tézé B, Gombert K, Mahler B, Hinnen F, Kühnast B, Dollé F, Dubertret B, Tavitian B. (2008). Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales. Bioconjug Chem, 19, 1921-6.
23. El-Ridy MS, Abdelbary A, Nasr EA, Khalil RM, Mostafa DM, El-Batal AI, Abd El-Alim SH. (2011). Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev Ind Pharm [Epub ahead of print].
24. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP. (2008). Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging, 27, 574-80. (Pubitemid 351354743)
25. Erdogan S, Roby A, Torchilin VP. (2006). Enhanced tumor visualization by gamma scintigraphy with 111In-labeled polychelating-polymercontaining immunoliposomes. Mol Pharm, 3, 525-30. (Pubitemid 44639129)
26. Fattal E, Barratt G. (2009). Temed section: Vector design and drug delivery review-Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Brit J Pharmacol, 157, 179-94.
27. Ferrara KW, Borden MA, Zhang H. (2009). Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res, 42, 881-92.
28. Ferrara KW, Seao JW, Zhang H. (2009). Imaging nanoparticle stability and activation in vivo. Proceedings of the 31st Annual International Conference of the IEEE EMBS; 2009 Sep 2-6; Minneapolis Minnesota, USA, pp. 4580-1.
29. Fukukawa K, Rossin R, Hagooly A, Pressly ED, Hunt JN, Messmore BW, Wooley KL, Welch MJ, Hawker CJ. (2008). Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications. Biomacromolecules, 9, 1329-39. (Pubitemid 351639589)
30. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. (1990). Efect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res, 50, 6371-8. (Pubitemid 20323703)
31. Goins B, Klipper R, Rudolph AS, Phillips W T. (1994). Use of Technetium-99m-liposomes in tumor imaging. J Nucl Med, 35, 1491-8. (Pubitemid 24280459)
32. Goto R, Kubo H, Okada S. (1989). Liposomes prepared from synthetic amphiphiles. I. Teir technetium labeling and stability. Chem Pharm Bull, 37, 1351-4. (Pubitemid 19151238)
33. Goyal P, Goyal K, Kumar SG, Singh A, Katare OP, Mishra DN. (2005). Liposomal drug delivery systems-clinical applications. Acta Pharmaceut, 55, 1-25. (Pubitemid 40562616)
34. Guilloteau, D., Vergote, J., Maia, S. (2007). Importance of radiopharmacy in hospital practice: application to Alzheimer and Parkinson's disease exploration. FABAD J Pharm Sci, 32, 41-8.
35. Halpenny DF, Burke JP, Lawlor GO, O'Connell M. (2009). Role of PET and combination PET/CT in the evaluation of patients with ?nfammatory bowel disease. Infamm Bowel Dis, 15, 951-8.
36. Hamoudeh M, Kamleh MA, Diab R, Fessi H. (2008). Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliver Rev, 60, 1329-46.
37. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JS. (2000). Biodistribution and pharmacokinetics of 111In-DTPA-labelled PEGylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer, 83, 232-8. (Pubitemid 30411723)
38. Hnatowich DJ, Friedman B, Clancy B, Novak M. (1981). Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. J Nucl Med, 22, 810-4. (Pubitemid 11057772)
39. Hnatyszyn HJ, Kossovsky N, Gelman A, Sponsler E. (1994). Drug delivery systems for the future. PDA J Pharm Sci Technol, 48, 247-54. (Pubitemid 24335202)
40. Hu H, Su L, Xu YQ, Zhang H, Wang LW. (2010). Behavioral and [F-18] fuorodeoxyglucose micropositron emission tomography imaging study in a rat chronic mild stress model of depression. Neuroscience, 169, 171-81.
41. Huynh NT, Roger E, Lautram N, Benoît JP, Passirani C. (2010). The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond), 5, 1415-33.
42. Ilica AT, Kocacelebi K, Savas R, Ayan A. (2011). Imaging of extranodal lymphoma with PET/CT. Clin Nucl Med, 36, e127-38.
43. Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed, 1, 297-315.
44. Ishiwata K, Tomura M, Ido T, Iwata R, Sato K, Hatazawa J, Kameyama M, Imahori Y. (1990). 6-[18F]Fluoro-L-fucose: a possible tracer for assessing glycoconjugate synthesis in tumors with positron emission tomography. J Nucl Med, 31, 1997-2003.
45. Janib SM, Moses AS, MacKay JA. (2010). Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev, 62, 1052-63.
46. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaf J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H. (2002). Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst, 94, 1484-93. (Pubitemid 35251753)
47. Kawaguchi AT, Haida M, Yamano M, Fukumoto D, Ogata Y, Tsukada H. (2010). Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates: an acute study. J Pharmacol Exp Ter, 332, 429-36.
48. Klajnert B, Bryszewska M. (2001). Dendrimers: properties and applications. Acta Biochim Pol, 48, 199-208. (Pubitemid 33632622)
49. Klunk WE, Engler H, Nordberg A. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol, 55, 306-19. (Pubitemid 38269583)
50. Koehler L, Graf F, Bergmann R, Steinbach J, Pietzsch J, Wuest F. (2010). Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors. Eur J Med Chem, 45, 727-37.
51. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N. (2004). Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer, 108, 301-6. (Pubitemid 37541787)
52. Kondo N, Tsukuda M, Nishimura G. (2011). Diagnostic sensitivity of (18)fuorodeoxyglucose positron emission tomography for detecting synchronous multiple primary cancers in head and neck cancer patients. Eur Arch Otorhinolaryngol. [Epub ahead of print].
53. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB. (2010). P-glycoprotein function at the blood-brain barrier in humans can be quantifed with the substrate radiotracer 11C-N-desmethyl- loperamide. J Nucl Med, 51, 559-66.
54. Kshirsagar NA. (2000). Drug delivery systems. Indian J Pharmacol, 32, S54-S61.
55. Kubo A, Nakamura K, Sammiya T, Katayama M, Hashimoto T, Hashimoto S, Kobayashi H, Teramoto T. (1993). Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer. Eur J Nucl Med, 20, 107-13. (Pubitemid 23075104)
56. Kulkarni M, Greiser U, O'Brien T, Pandit A. (2010). Liposomal gene delivery mediated by tissue-engineered scafolds. Trends Biotechnol, 28, 28-36.
57. Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. (2010). Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2, 35-47.
58. Kumar R, Bhargava P, Bozkurt MF, Zhuang H, Potenta S, Alavi A. (2003). Positron emission tomography imaging in evaluation of cancer patients. Indian J Cancer, 40, 87-100. (Pubitemid 38698419)
59. Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. (2008). Oncologic PET tracers beyond [18F]FDG and the novel quantitative approaches in PET imaging. Quarterly l Nucl Med Mol Imaging, 52, 50-65. (Pubitemid 351351044)
60. Langer R. (1990). New methods of drug delivery. Science, 249, 1527-33.
61. Lassonde M, Sauerwein HC, Gallagher A, Teriault M, Lepore F. (2006). Neuropsychology: traditional and new methods of investigation. Epilepsia, 47, 9-13. (Pubitemid 44684612)
62. Lee CM, Farde L. (2006). Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci, 27, 310-6. (Pubitemid 43870125)
63. Lembo D, Cavalli R. (2010). Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother, 21, 53-70.
64. Lindner O, Sörensen J, Vogt J, Fricke E, Baller D, Horstkotte D, Burchert W. (2006). Cardiac efFFFFFB01ciency and oxygen consumption measured with 11C-Acetate PET after long-term cardiac resynchronization therapy. J Nucl Med, 47, 378-83. (Pubitemid 46768478)
65. Liu JH, Yang ST, Wang H, Liu Y. (2010). Advances in biodistribution study and tracing methodology of carbon nanotubes. J Nanosci Nanotechnol, 10, 8469-81.
66. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR efect in macromolecular therapeutics: a review. J Control Release, 65, 271-84. (Pubitemid 30122932)
67. Marik J, Tartis MS, Zhang H, Fung JY, Kheirolomoom A, Sutclife JL, Ferrara KW. (2007). Long-circulating liposomes radiolabeled with [18F]fuorodipalmitin ([18F]FDP). Nucl Med Biol, 34, 165-71. (Pubitemid 46241896)
68. Massoud TF, Gambhir SS. (2003). Molecular imaging in living subjects: Seeing fundamental biological process in a new light. Genes Dev, 17, 545-80. (Pubitemid 36307540)
69. Matsumura Y, Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res, 46, 6387-92. (Pubitemid 17221789)
70. Mayer C. (2005). Nanocapsules as drug delivery systems. Int J Artif Organs, 28, 1163-71. (Pubitemid 43085409)
71. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, Zanzonico P, Smith-Jones P, Larson SM. (2011). Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release, 149, 292-8.
72. Medina OP, Zhu Y, Kairemo K. (2004). Targeted liposomal drug delivery in cancer. Curr Pharm Des, 10, 2981-9. (Pubitemid 39214006)
73. Miller JC, Phill D., PET/CT for tumor imaging. (2004). Radiology Rounds, 2, 1-3.
74. Mirafzali Z. (2011). How many liposome based drugs are in the market? (http://www.quora.com/How-many-liposome-baseddrugs-are-in-the-market).
75. Mistur R, Mosconi L, De Santi S, Guzman M, Li Y, Tsui W, de Leon MJ. (2009). Current challenges for the early detection of Alzheimer's disease: brain imaging and CSF studies. J Clin Neurol, 5, 153-66.
76. Mitra A, Nan A, Line BR, Ghandehari H. (2006). Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des, 12, 4729-49. (Pubitemid 44841764)
77. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, De Leon MJ. (2010). Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis, 20, 843-54.
78. Muggia F. (1999). Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res, 5, 7-8. (Pubitemid 29045171)
79. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. (2007). In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med, 48, 1313-9. (Pubitemid 47242797)
80. Nandhagopal R, McKeown MJ, Stoessl AJ. (2008). Invited article: functional imaging in Parkinson's disease. Neurology, 70, 1478-88. (Pubitemid 351521943)
81. Neerunjun ED, Hunt R, Gregoriadis G. (1977). Fate of a liposomeassociated agent injected into normal and tumour-bearing rodents: attempts to improve localization in tumour tissues. Biochem Soc Trans, 5, 1380-3. (Pubitemid 8205973)
82. Ogihara-Umeda I, Sasaki T, Nishigori H. (1992). Development of a liposome-encapsulated radionuclide with preferential tumor accumulation-the choice of radionuclide and chelating ligand. Int J Rad Appl Instrum B, 19, 753-7.
83. Oku N, Namba Y. (1994). Long-circulating liposomes. Crit Rev Ter Drug Carrier Syst, 11, 231-70.
84. Oku N, Yamashita M, Katayama Y, Urakami T, Hatanaka K, Shimizu K, Asai T, Tsukada H, Akai S, Kanazawa H. (2011). PET imaging of brain cancer with positron emitter-labeled liposomes. Int J Pharm, 403, 170-7.
85. Olanow CW, Watts RL, Koller WC. (2001). An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology, 56, 1-88.
86. Ostro MJ, Cullis PR. (1989). Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm, 46, 1576-87. (Pubitemid 19201630)
87. Pandya NM, Dhalla NS, Santani DD. (2006). Angiogenesis-a new target for future therapy. Vascul Pharmacol, 44, 265-74.
88. Paoli EE, Kruse DE, Seo JW, Zhang H, Kheirolomoom A, Watson KD, Chiu P, Stahlberg H, Ferrara KW. (2010). An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: importance of formulation. J Control Release, 143, 13-22.
89. Peng J, He Y, Xu J, Sheng J, Cai S, Zhang Z. (2011). Detection of incidental colorectal tumours with (18)F-labelled 2-fuoro-2-deoxyglucosepositron emission tomography/computed tomography scans: results of a prospective study. Colorectal Dis, 13, e374-8.
90. Petersen AL, Binderup T, Rasmussen P, Henriksen R, Elema DR, Kær A, Andresen TL. (2011). 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials, 32, 2334-41.
91. Phillips W T, Goins BA, Bao A. (2009). Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 1, 69-83.
92. Piccini P, Brooks DJ. (2006). New developments of brain imaging for Parkinson's disease and related disorders. Movement Disord, 21, 2035-41. (Pubitemid 46140409)
93. Pisal DS, Kosloski MP, Balu-Iyer S V. (2010). Delivery of therapeutic proteins. J Pharm Sci, 99, 2557-75.
94. Qin S, Seo JW, Zhang H, Qi J, Curry FRE, Ferrara W. (2009). An imagingdriven model for liposomal stability and circulation. Mol Pharm, 7, 12-21.
95. Ravi-Kumar MNV. (2000). Nano and microparticles as controlled drug delivery devices. J Pharm Pharmaceut Sci, 3, 234-58.
96. Richardson VJ, Jeyasingh K, Jewkes R F, Ryman BE, Tattersall MH. (1977). Properties of [99mTc] technetium-labelled liposomes in normal and tumour-bearing rats. Biochem Soc Trans, 5, 290-1. (Pubitemid 8063587)
97. Robinon DH, Mauger JW. (1991). Drug delivery systems. Am J Hosp Pharm, 48, S14-23.
98. Rosa-Neto P, Leuzy A. (2009). Molecular imaging of Alzheimer's disease using PET. The Canadian Review of Alzheimer's Disease and Other Dementias, 18-26. (http://www.stacommunications.com/adreview.html).
99. Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. (2010). Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine, 5, 783-802.
100. Saha GB. (2004). Fundamentals of nuclear pharmacy. New York, USA: Springer.
101. Sawant R, Torchilin VP. (2010). Intracellular transduction using cellpenetrating peptides. Mol BioSyst, 6, 628-40.
102. Scheer MG, Stollman TH, Boerman OC, Verrijp K, Sweep FC, Leenders WP, Ruers TJ, Oyen WJ. (2008). Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer, 44, 1835-40.
103. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. (2010). Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging, 3, 623-40.
104. Schmidt ME, Andrews RD, Van der Ark P, Brown T, Mannaert E, Steckler T, de Hoon J, Van Laere K. (2010). Dose-dependent efects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology, 208, 109-19.
105. Seo JW, Mahakian LM, Kheirolomoom A, Zhang H, Meares CF, Ferdani R, Anderson CJ, Ferrara, KW. (2010). Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator efects. Bioconjugate Chem, 21, 1206-15.
106. Seo JW, Qin S, Mahakian LM, Watson KD, Kheirolomoom A, Ferrara KW. (2011). Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. J Control Release, 151, 28-34.
107. Seo JW, Zhang H, Kukis DL, Meares CF, Ferrara KW. (2008). A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem, 19, 2577-84.
108. Sheikine Y, Akram K. (2010). FDG-PET imaging of atherosclerosis: do we know what we see? Atherosclerosis, 211, 371-80.
109. Shoghi-Jadid K, Small GW, Agdeppa ED. 2002 Localization of neurofbrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriat Psychiat 10, 24-35. (Pubitemid 34052900)
110. Silindir M, Erdoian S, Özer AY, Doian L, Tuncel M, Uiur Ö,Torchilin VP. (2009). Tumor targeted nanosized liposome-based diagnostic agents for hybrid imaging systems. In: Hncal A A, Çelebi N, Yüksel N, Eds. Proceedings of the 3rd BBBB Conference on Pharmaceutical Sciences; 2009 Oct 26-28; Antalya, Turkey, pp. 129-130.
111. Silindir M, Erdoian S, Özer AY, Doian L, Tuncel M, Uiur Ö,Torchilin VP. (2010). Iopromide and Tc-99m loaded nano-sized tumor targeted liposomes for tumor imaging by SPECT/CT. In: Storm G, Fuentes M, Oberleithner H, Palacio F, Tomas D, Eds. Proceedings of the European Science Foundation (ESF) Research Congress-Nanomedicine: Reality Now and Soon; 2010 Oct 23-28; San Feliu de Guixols, Spain, pp. 28-29.
112. Silindir M, Özer AY. (2008). Recently developed radiopharmaceuticals for positron emission tomography (PET). FABAD J Pharm Sci, 33, 153-62.
113. Singh S. (2010). Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol, 10, 7906-18.
114. Sofou S. (2008). Radionuclide carriers for targeting of cancer. Int J Nanomedicine, 3, 181-99. (Pubitemid 352037851)
115. Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. (2010). PET/CT in the evaluation of infammatory bowel disease: studies in patients before and after treatment. Mol Imaging Biol, 12, 85-8.
116. Sun L, Wu H, Guan Y. (2007). Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroentero, 13, 2775-83. (Pubitemid 47007891)
117. Sun Y, Yu M, Liang S, Zhang Y, Li C, Mou T, Yang W, Zhang X, Li B, Huang C, Li F. (2011). Fluorine-18 labeled rare-earth nanoparticles for positron emission tomography (PET) imaging of sentinel lymph node. Biomaterials, 32, 2999-3007.
118. Tajouri TH, Chareonthaitawee P. (2010). Myocardial viability imaging and revascularization in chronic ischemic left ventricular systolic dysfunction. Expert Rev Cardiovasc Ter, 8, 55-63.
119. Takano A. (2010). The application of PET technique for the development and evaluation of novel antipsychotics. Curr Pharm Des, 16, 371-7.
120. Tartis MS, Kruse DE, Zheng H, Zhang H, Kheirolomoom A, Marik J, Ferrara KW. (2008). Dynamic microPET imaging of ultrasound contrast agents and lipid delivery. J Control Release, 131, 160-6.
121. Tiwari VN, Kiyono Y, Kobayashi M, Mori T, Kudo T, Okazawa H, Fujibayashi Y. (2010). Automatic labeling method for injectable 15O-oxygen using hemoglobin-containing liposome vesicles and its application for measurement of brain oxygen consumption by PET. Nucl Med Biol, 37, 77-83.
122. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GGM. (2003). Cell transfection in vitro and in vivo with nontoxic TAT peptideliposome-DNA complexes. P Natl A Sci, 100, 1972-77. (Pubitemid 36254558)
123. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. (2001). TAT peptide on the surface of liposomes afords their efcient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. P Natl Acad Sci USA, 17, 8786-91. (Pubitemid 32678105)
124. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. (2001). TAT peptide on the surface of liposomes afords their efcient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA, 98, 8786-91. (Pubitemid 32678105)
125. Torchilin VP. (2000). Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol, 1, 183-215.
126. Torchilin VP. (2006). Multifunctional nanocarriers. Adv Drug Deliver Rev, 58, 1532-55. (Pubitemid 44822608)
127. Torchilin VP. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharm Res, 24, 1-16. (Pubitemid 44902565)
128. Torchilin VP. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol, 197, 3-53.
129. Trubetskoy VS, Torchilin VP. (1994). New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. J Liposome Res, 4, 961-80.
130. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, Wester H J, Schwaiger M, Krause B J. (2008). [11C] Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 35, 689-95.
131. Turner AF, Presant CA, Proftt RT, Williams LE, Winsor DW, Werner JL. (1988). In-111-labeled liposomes: dosimetry and tumor depiction. Radiology, 166, 761-5. (Pubitemid 18058941)
132. Uekama K, Otagiri M. (1987). Cyclodextrins in drug carrier systems. Crit Rev Ter Drug Carrier Syst, 3, 1-40. (Pubitemid 17231927)
133. Urakami T, Akai S, Katayama Y, Harada N, Tsukada H, Oku N. (2007). Novel amphiphilic probes for [18F]-radiolabeling preformed liposomes and determination of liposomal trafcking by positron emission tomography. J Med Chem, 50, 6454-7. (Pubitemid 350309083)
134. Urakami T, Kawaguchi AT, Akai S, Hatanaka K, Koide H, Shimizu K, Asai T, Fukumoto D, Harada N, Tsukada H, Oku N. (2009). In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. Artif Organs, 33, 164-8.
135. Vallabhajosula S. (2007). 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med, 37, 400-19. (Pubitemid 47505221)
136. Vasant VR. (2004). Drug delivery systems. USA: CRS Press Pharmacology&Toxicology Series.
137. Verel I, Visser GWM, Van Dongen GA. (2005). The promise of immuno-PET in radioimmunotherapy. J Nucl Med, 46, 164S-71S. (Pubitemid 47619032)
138. Wagner HN. (1995). Principles of nuclear medicine. Philadelphia, USA: W B Saunders Company.
139. Weissig V, Boddapati SV, Cheng SM, D'Souza GG. (2006). Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J Liposome Res, 16, 249-64. (Pubitemid 44358998)
140. Weissig V, Whiteman KR, Torchilin VP. (1998). Accumulation of proteinloaded long-circulating micelles and liposomes in subcutaneous lewis lung carcinoma in mice. Pharm Res, 15, 1552-6. (Pubitemid 28465741)
141. Weissig V. (2010). Liposomes-Methods and Protocols. USA: Humana Press.
142. Wunderlich G, Schiller E, Bergmann R, Pietzsch HJ. (2010). Comparison of the stability of Y-90-, Lu-177-and Ga-68-labeled human serum albumin microspheres (DOTA-HSAM). Nucl Med Biol, 37, 861-7.
143. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K, Ohta T. (2010). Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol, 66, 745-53.
144. Yakushev IY, Dupont E, Buchholz HG, Tillmanns J, Debus F, Cumming P, Heimann A, Fellgiebel A, Luhmann HJ, Landvogt C, Werhahn KJ, Schreckenberger M, Potschka H, Bartenstein P. (2010). In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia, 51, 415-22.
145. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Xiao Y, Yang Y, Zhang Y, Nickles RJ, Cai W, Steeber DA, Gong S. (2011). cRGD-functionalized, DOX-conjugated, and (64)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials, 32, 4151-60.
146. Yokoyama M. (2010). Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv, 7, 145-58.
147. Zavaleta CL, Phillips W T, Soundararajan A, Goins BA. (2007). Pharmaceutical Nanotechnology-Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm, 337, 316-28. (Pubitemid 46756055)
148. Zavaleta CL, Phillips W T, Soundararajan A, Goins BA. (2007). Pharmaceutical Nanotechnology-use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm, 337, 316-28. (Pubitemid 46756055)
149. Zheng J, Allen C, Serra S, Vines D, Charron M, Jafray DA. (2010). Liposome contrast agent for CT-based detection and localization of neoplastic and infammatory lesions in rabbits: validation with FDG-PET and histology. Contrast Media Mol Imaging, 5, 147-54.
150. Zimmer L, Rbah L, Giacomelli F, Le Bars D, Renaud B. (2003). A reduced extracellular serotonin level increases the 5-HT1A PET ligand 18F-MPPF binding in the rat hippocampus. J Nucl Med, 44, 1495-501. (Pubitemid 39663366)